公开(公告)号：WO2019118046A1

公开(公告)日：2019-06-20

申请号：PCT/US2018/052829

申请日：2018-09-26

Applicant: L'OREAL ,  YALE UNIVERSITY

Inventor： GEORGE, Kelly, Marie ,  PAN, Zhi ,  MARROT, Laurent ,  WANG, Miao ,  BRASH, Douglas, Edgar ,  PREMI, Sanjay ,  GONCALVES, Leticia, C.P.

IPC: A61Q17/04

CPC classification number: A61K36/704 ,  A61K8/31 ,  A61K8/35 ,  A61K8/36 ,  A61K8/365 ,  A61K8/40 ,  A61K8/44 ,  A61K8/4926 ,  A61K8/498 ,  A61K8/9717 ,  A61K8/9789 ,  A61K31/01 ,  A61K31/015 ,  A61K31/12 ,  A61K31/19 ,  A61K31/192 ,  A61K31/353 ,  A61K31/366 ,  A61K31/44 ,  A61K36/04 ,  A61K36/287 ,  A61K36/355 ,  A61K36/48 ,  A61K36/539 ,  A61K47/12 ,  A61K47/24 ,  A61Q19/004

Abstract: A method for decreasing formation of one or more chemiexcitation-induced dark cyclobutane pyrimidine dimers (dCPDs) in a cell or DNA molecule in a subject, who has been exposed to UV radiation, is provided. The method comprises administering to the subject an effective amount of a dCPD quencher within 8 hours after the exposure. The dCPD quencher is selected from the group consisting of ellagic acid, Porphyra Umbilicalis Extract (including Porphyra Umbilicalis Extract (and) Sodium Lactate (and) Lecithin), mycosporine-like amino acids (MAAs) and synthetic analogues thereof, Scutellaria Baicalensis Root Extract, Chrysanthemum Morifolium Leaf Extract, ferulic acid, fused-ring cyanoacrylates, curcumin, epigallocatechin gallate, Scutellaria Baicalensis Root Extract (and) Acacia Catechu Wood Extract, sorbic acid, Polygonum Cuspidatum Root Extract, Acacia Catechu Extract, dipicolinic acid, squalene, Lonicera Japonica (Honeysuckle) Flower Extract, beta-carotene and combinations thereof. The dCPD quencher may be administered to the subject in the absence of UV radiation.

公开(公告)号：WO2019106626A1

公开(公告)日：2019-06-06

申请号：PCT/IB2018/059525

申请日：2018-11-30

Applicant: LEWANDOWSKA, Agata

Inventor： LEWANDOWSKA, Agata

IPC: A61K31/015 ,  A61K31/19 ,  A61K31/202 ,  A61K31/25 ,  A61K31/355 ,  A61K31/375 ,  A61K33/04 ,  A61K33/30 ,  A61P17/18 ,  A61P29/00 ,  A61P1/04

CPC classification number: A61K31/19 ,  A61K31/015 ,  A61K31/202 ,  A61K31/25 ,  A61K31/355 ,  A61K31/375 ,  A61K33/04 ,  A61K33/30 ,  A61P1/04 ,  A61P17/18 ,  A61P29/00 ,  A61K2300/00

Abstract: The invention relates to a composition for oral administration, the use of the composition for prevention and treatment of mucositis, and the method of treating mucositis using this composition in patients before and after the systemic treatment.

公开(公告)号：WO2019100053A1

公开(公告)日：2019-05-23

申请号：PCT/US2018/061971

申请日：2018-11-20

Applicant: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.

Inventor： YIN, Hang ,  XIE, Liwei ,  YIN, Amelia Yao-Ye

IPC: A61P21/04 ,  A61K31/015 ,  A61K31/277

CPC classification number: A61K31/7105 ,  A61K9/0019 ,  A61K31/015 ,  A61K31/277 ,  A61P21/04 ,  A61P25/14 ,  C12Q1/6876

Abstract: Compositions and methods for modulating HIF-2α to meditate of hypoxia signaling in satellite cells and applications thereof for improving skeletal muscle generation and repair are provided. For example, methods of enhancing, increasing, accelerating or/and otherwise improving skeletal muscle generation or regeneration in a subject in need thereof are disclosed. In some embodiments, the methods include administering the subject an effective amount of HIF-2α inhibitor. The HIF-2α inhibitor can be effective to, for example, increase muscle satellite cell proliferation, differentiation, or a combination thereof in a subject. Composition and methods for improving respiration, and reducing or preventing the development or progression of fibrosis are also provided. The disclosed compositions and methods are particularly useful for treating muscular dystrophies, myopathies, and other muscle-related diseases and disorders.

公开(公告)号：WO2019090039A1

公开(公告)日：2019-05-09

申请号：PCT/US2018/058887

申请日：2018-11-02

Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES ,  HOON, Mark A. ,  SOLINSKI, Hans Juergen ,  INGLESE, James ,  DRANCHAK, Patricia

Inventor： HOON, Mark A. ,  SOLINSKI, Hans Juergen ,  INGLESE, James ,  DRANCHAK, Patricia

IPC: A61K31/422 ,  A61K31/4184 ,  A61K31/015 ,  A61K31/42 ,  A61K31/437 ,  A61K31/439 ,  A61K31/4545 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/519 ,  A61K31/55 ,  A61K31/5513 ,  A61K31/5517 ,  A61P17/04 ,  A61P43/00

CPC classification number: C07D471/04 ,  A61K31/015 ,  A61K31/4184 ,  A61K31/42 ,  A61K31/422 ,  A61K31/437 ,  A61K31/439 ,  A61K31/4545 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/519 ,  A61K31/55 ,  A61K31/5513 ,  A61K31/5517 ,  A61P17/04 ,  A61P43/00 ,  C07D413/12 ,  C07D487/04

Abstract: Pharmaceutical compositions comprising a molecular inhibitor of Npr1 are disclosed. Also disclosed are methods of treating, reducing, or preventing acute and/or chronic pruritus in a mammal comprising administering a pharmaceutical composition comprising a molecular inhibitor of Npr1.

公开(公告)号：WO2018236957A1

公开(公告)日：2018-12-27

申请号：PCT/US2018/038430

申请日：2018-06-20

Applicant: NEXIEN BIOPHARMA, INC.

Inventor： FRIEDLAND, Jeffrey ,  KLUMPERS, Linda

IPC: A61K31/352 ,  A61K31/01 ,  A61P43/00 ,  A61P25/00

CPC classification number: A61P25/00 ,  A61K31/015 ,  A61K31/045 ,  A61K31/05 ,  A61K31/22 ,  A61K31/352 ,  A61P43/00 ,  A61K2300/00

Abstract: Methods and compositions for treating restless legs syndrome.

公开(公告)号：WO2018205038A1

公开(公告)日：2018-11-15

申请号：PCT/CA2018/050572

申请日：2018-05-14

Applicant: TETRA BIO-PHARMA INC.

Inventor： RINGUETTE, Randy ,  CAMPBELL, Charles

IPC: A61K31/352 ,  A61K31/01 ,  A61K31/015 ,  A61K31/045 ,  A61K31/05 ,  A61K31/15 ,  A61K31/164 ,  A61K31/165 ,  A61K31/198 ,  A61K31/22 ,  A61K31/5383 ,  A61K31/57 ,  A61K36/185 ,  C07C11/21 ,  C07C13/21 ,  C07C13/271 ,  C07C13/42 ,  C07C233/01 ,  C07C233/17 ,  C07C233/18 ,  C07C39/19 ,  C07C39/23 ,  C07C69/67 ,  C07D311/60 ,  C07D311/80 ,  C07D498/06

CPC classification number: A61K36/185 ,  A61K31/01 ,  A61K31/015 ,  A61K31/045 ,  A61K31/05 ,  A61K31/15 ,  A61K31/164 ,  A61K31/165 ,  A61K31/198 ,  A61K31/22 ,  A61K31/352 ,  A61K31/5383 ,  A61K45/06 ,  A61K2300/00

Abstract: Pharmaceutical compositions comprising a mixture of cannabinoids and terpenes and use thereof in the treatment of select disorders mediated by the Hedgehog (HH) signaling pathway are disclosed. In preferred embodiments, the components of the composition synergistically inhibit HH signaling such that they serve to treat cancer and ocular disorders associated with aberrant neovascularization (such as age-related macular degeneration). The cannabinoids to be used include phytocannabinoids (such as tetrahydrocannabinol and cannabidiol), endogenous cannabinoids (such as the N-acylethanolamides), or synthetic cannabinoids. Preferred terpenes for use include those that naturally occur in Cannabis plants (such as pinene, limonene, linalool, and phytol).

公开(公告)号：WO2017127306A1

公开(公告)日：2017-07-27

申请号：PCT/US2017/013560

申请日：2017-01-13

Applicant: ARISAN THERAPEUTICS

Inventor： PLEWE, Michael ,  BROWN, Eric ,  GANTLA, Vidyasagar ,  HENKEL, Gregory ,  MCCORMACK, Kenneth ,  SOKOLOVA, Nadezda

IPC: A61K31/015 ,  A61K31/135 ,  A61K31/165 ,  C07C13/28 ,  C07C13/54 ,  C07C13/573

CPC classification number: A61K31/015 ,  A61K31/135 ,  A61K31/165 ,  C07C217/58 ,  C07C233/41 ,  C07C233/43 ,  C07C233/62 ,  C07C235/40 ,  C07C237/24 ,  C07C275/26 ,  C07C2601/14 ,  C07C2603/74 ,  C07D205/04 ,  C07D205/12 ,  C07D209/94 ,  C07D211/34 ,  C07D211/56 ,  C07D211/58 ,  C07D211/60 ,  C07D211/62 ,  C07D213/74 ,  C07D213/75 ,  C07D213/82 ,  C07D233/64 ,  C07D243/08 ,  C07D295/03 ,  C07D295/088 ,  C07D295/13 ,  C07D295/185 ,  C07D295/192 ,  C07D295/26 ,  C07D295/32 ,  C07D451/04 ,  C07D453/02 ,  C07D487/04 ,  C07D487/06 ,  C07D487/10

Abstract: Compounds of structural Formula (I) were developed for the treatment of infections by filoviruses including Ebolavirus and Marburgvirus.

Abstract translation: 开发了结构式（I）的化合物用于治疗包括埃博拉病毒和马尔堡病毒在内的病毒的感染。

公开(公告)号：WO2017096165A1

公开(公告)日：2017-06-08

申请号：PCT/US2016/064619

申请日：2016-12-02

Applicant: AGIOS PHARMACEUTICALS, INC.

Inventor： MARJON, Katya ,  CHOE, Sung Eun

IPC: A61K31/015 ,  A61K45/00 ,  A61K31/505 ,  A61P35/00

CPC classification number: A61K31/015 ,  A61K31/505 ,  A61K45/00

Abstract: The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with a MAT2A inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by a MAT2A inhibitor, comprising assessing whether the tumor cell is absent an MTAP gene whereby cells that are MTAP null are sensitive to inhibition by MAT2A inhibitors.

Abstract translation: 本发明提供了用于预测用MAT2A抑制剂治疗癌症患者的有效性的诊断和预后方法。 提供了用于预测肿瘤细胞生长对MAT2A抑制剂抑制的敏感性的方法，包括评估肿瘤细胞是否不存在MTAP基因，由此MTAP无效的细胞对MAT2A抑制剂的抑制敏感。

公开(公告)号：WO2017089465A1

公开(公告)日：2017-06-01

申请号：PCT/EP2016/078686

申请日：2016-11-24

Applicant: GRASL, Jürgen ,  KOWARIK, Dietmar

Inventor： GRASL, Jürgen ,  KOWARIK, Dietmar

IPC: A61Q19/00 ,  A61K31/00 ,  A61L26/00 ,  A23L33/00 ,  A23L33/10 ,  A61K9/70 ,  A61K8/02

CPC classification number: A23L33/10 ,  A23L33/40 ,  A61K8/0208 ,  A61K8/27 ,  A61K8/42 ,  A61K8/673 ,  A61K8/676 ,  A61K8/735 ,  A61K8/97 ,  A61K31/015 ,  A61K31/045 ,  A61K31/047 ,  A61K31/065 ,  A61K31/122 ,  A61K31/164 ,  A61K31/197 ,  A61K31/198 ,  A61K31/375 ,  A61K31/4188 ,  A61K31/519 ,  A61K31/59 ,  A61K31/716 ,  A61K31/728 ,  A61K33/04 ,  A61K33/30 ,  A61K36/82 ,  A61K36/899 ,  A61K2800/92 ,  A61Q1/00 ,  A61K2300/00

Abstract: A nutritional supplement formulation is provided, which contains a wound healing substance for use in the pre- and/or post-treatment of tattooing, for use in improving the coloring and/or color saturation of the tattoo and/or for use in improving the skin appearance after tattooing.

Abstract translation: 提供营养补充制剂，其包含用于纹身处理前和/或后处理的伤口愈合物质，用于改善纹身的着色和/或颜色饱和度 和/或用于改善纹身后的皮肤外观。

公开(公告)号：WO2017002120A1

公开(公告)日：2017-01-05

申请号：PCT/IL2016/050702

申请日：2016-06-30

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： KRIZHANOVSKY, Valery ,  GAL, Hilah

IPC: A61P29/00 ,  A61P1/16 ,  A61P17/00 ,  A61P43/00 ,  A61K31/33 ,  A61K31/4427 ,  A61K31/4709 ,  A61K31/429 ,  A61K31/015 ,  A61K31/357 ,  A61K31/7004 ,  C07H11/00 ,  C07D493/02 ,  C07D487/02 ,  C07D213/84 ,  C07C205/16 ,  C07C205/40 ,  C07D409/12 ,  C07D217/24 ,  C07C49/603 ,  C07D513/02 ,  C07D257/04 ,  C07D213/71 ,  C07D417/12 ,  C07D277/62 ,  C07D417/04 ,  C07D333/20 ,  C07D277/70 ,  A61Q19/08 ,  C07H13/02 ,  A61K31/635

CPC classification number: A61K31/015 ,  A61K31/33 ,  A61K31/357 ,  A61K31/429 ,  A61K31/4427 ,  A61K31/4709 ,  A61K31/635 ,  A61K31/7004 ,  A61Q19/08 ,  C07C49/747 ,  C07C49/813 ,  C07C205/16 ,  C07C205/40 ,  C07C251/38 ,  C07C251/82 ,  C07C2601/16 ,  C07C2603/28 ,  C07D213/71 ,  C07D213/84 ,  C07D217/24 ,  C07D257/04 ,  C07D277/62 ,  C07D277/70 ,  C07D333/20 ,  C07D409/12 ,  C07D417/04 ,  C07D417/12 ,  C07D487/02 ,  C07D493/02 ,  C07D513/02 ,  C07H13/00

Abstract: Compounds useful for selectively eliminating senescent cells, compositions comprising same and uses thereof in treating diseases and disorders in which selective elimination of senescent cells is beneficial are provided. The compounds are selectively represented by the following Formulae (I) and (II); with the variables being as defined in the specification. Also provided is a screening assay for identifying compounds that selectively inhibit senescent cells.

Abstract translation: 提供了用于选择性消除衰老细胞的化合物，包含其的组合物及其用于治疗其中选择性消除衰老细胞有益的疾病和病症的用途。 所述化合物由下式（I）和（II）选择性地表示; 变量如规范中所定义。 还提供了用于鉴定选择性抑制衰老细胞的化合物的筛选测定。